ATE292983T1 - Chimäres retrovirus/adenovirus system - Google Patents
Chimäres retrovirus/adenovirus systemInfo
- Publication number
- ATE292983T1 ATE292983T1 AT97948396T AT97948396T ATE292983T1 AT E292983 T1 ATE292983 T1 AT E292983T1 AT 97948396 T AT97948396 T AT 97948396T AT 97948396 T AT97948396 T AT 97948396T AT E292983 T1 ATE292983 T1 AT E292983T1
- Authority
- AT
- Austria
- Prior art keywords
- retroviral
- vector
- functions
- chimeric
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3132396P | 1996-11-19 | 1996-11-19 | |
US3708197P | 1997-02-04 | 1997-02-04 | |
PCT/US1997/021169 WO1998022143A1 (en) | 1996-11-19 | 1997-11-19 | Chimeric retrovirus/adenovirus system |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE292983T1 true ATE292983T1 (de) | 2005-04-15 |
Family
ID=26707084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97948396T ATE292983T1 (de) | 1996-11-19 | 1997-11-19 | Chimäres retrovirus/adenovirus system |
Country Status (8)
Country | Link |
---|---|
US (1) | US6333030B1 (de) |
EP (1) | EP0956052B1 (de) |
JP (1) | JP4214239B2 (de) |
AT (1) | ATE292983T1 (de) |
AU (1) | AU728610B2 (de) |
CA (1) | CA2272121A1 (de) |
DE (1) | DE69733035T2 (de) |
WO (1) | WO1998022143A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010006629A1 (en) * | 1993-10-25 | 2001-07-05 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
US6210939B1 (en) | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
DE69434594T2 (de) * | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
US20060275261A1 (en) * | 1993-10-25 | 2006-12-07 | Canji, Inc. | Adenoviral vectors having a protein IX deletion |
US8703480B1 (en) | 1997-03-21 | 2014-04-22 | Enzo Therapeutics, Inc. | Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells |
WO1998042856A1 (en) * | 1997-03-21 | 1998-10-01 | Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. | Vectors and viral vectors, and packaging cell lines for propagating same |
AU6962698A (en) | 1997-04-11 | 1998-11-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Transgenomic viruses and the use thereof |
WO1999044423A1 (en) * | 1998-03-03 | 1999-09-10 | The Uab Research Foundation | Amplification of gene transfer and gene therapy by controlled replication |
US20060183228A1 (en) * | 1998-03-24 | 2006-08-17 | Enzo Therapeutics, Inc. | Viral vectors with surface or envelope components |
FR2778670B1 (fr) | 1998-05-18 | 2002-12-13 | Rhone Poulenc Rorer Sa | Methodes et compositions pour la production de particules virales |
WO2000017376A1 (en) * | 1998-09-22 | 2000-03-30 | The Governement Of The United States Of America, As Represented By The Secretary Of The Departement Of Health And Human Services | Replication deficient retroviral vector system and methods of using |
US7052904B2 (en) | 2000-01-31 | 2006-05-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Hybrid adeno-retroviral vector for the transfection of cells |
WO2001092550A2 (en) * | 2000-05-31 | 2001-12-06 | Human Gene Therapy Research Institute | Methods and compositions for efficient gene transfer using transcomplementary vectors |
US7226779B2 (en) | 2001-01-30 | 2007-06-05 | The United States Of America As Represented By The Department Of Health And Human Services | Hybrid adenoviral vector |
WO2002092619A2 (en) | 2001-05-14 | 2002-11-21 | The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
WO2003029433A2 (en) * | 2001-10-04 | 2003-04-10 | Aguilar-Cordova Carlos Estuard | Chimeric viral vectors for gene therapy |
US20070037284A1 (en) * | 2003-06-04 | 2007-02-15 | Enzo Therapeutics, Inc. | Vectors for expressing exogenous gene or exogenous nucleic acid sequences |
ES2292271B1 (es) * | 2004-05-20 | 2009-02-16 | Proyecto De Biomedicina Cima, S.L. | Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales. |
WO2011123518A1 (en) | 2010-03-31 | 2011-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
WO2021158962A2 (en) | 2020-02-06 | 2021-08-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors targeting defective dna repair proteins |
US10822379B1 (en) | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000503534A (ja) * | 1996-01-05 | 2000-03-28 | ジェネティック セラピー,インコーポレイテッド | アデノウイルスベクターのリコンビナーゼ媒介生成 |
-
1997
- 1997-11-19 AT AT97948396T patent/ATE292983T1/de not_active IP Right Cessation
- 1997-11-19 EP EP97948396A patent/EP0956052B1/de not_active Expired - Lifetime
- 1997-11-19 JP JP52385598A patent/JP4214239B2/ja not_active Expired - Fee Related
- 1997-11-19 DE DE69733035T patent/DE69733035T2/de not_active Expired - Lifetime
- 1997-11-19 AU AU54475/98A patent/AU728610B2/en not_active Ceased
- 1997-11-19 WO PCT/US1997/021169 patent/WO1998022143A1/en active IP Right Grant
- 1997-11-19 US US08/974,113 patent/US6333030B1/en not_active Expired - Fee Related
- 1997-11-19 CA CA002272121A patent/CA2272121A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1998022143A1 (en) | 1998-05-28 |
EP0956052A4 (de) | 2001-05-02 |
DE69733035T2 (de) | 2005-11-24 |
AU728610B2 (en) | 2001-01-11 |
DE69733035D1 (en) | 2005-05-19 |
EP0956052B1 (de) | 2005-04-13 |
CA2272121A1 (en) | 1998-05-28 |
JP2001509009A (ja) | 2001-07-10 |
US6333030B1 (en) | 2001-12-25 |
AU5447598A (en) | 1998-06-10 |
JP4214239B2 (ja) | 2009-01-28 |
EP0956052A1 (de) | 1999-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE292983T1 (de) | Chimäres retrovirus/adenovirus system | |
Feng et al. | Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector | |
AU737801B2 (en) | Lentiviral vectors | |
US6323031B1 (en) | Lentiviral vectors derived from SIVagm, methods for their preparation and their use for gene transfer into mammalian cells | |
US6761884B1 (en) | Vectors including foreign genes and negative selective markers | |
US7303910B2 (en) | Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site | |
DE69829471D1 (de) | Auf lentivirus basierende gentransfer-vektoren | |
Pizzato et al. | Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer | |
US20080124308A1 (en) | Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped With Arenavirus Glycoproteins | |
WO1999058701A1 (en) | Novel lentiviral packaging cells | |
WO2003093417A3 (en) | Lentiviral vector particles resistant to complement inactivation | |
US20020034393A1 (en) | Vector | |
Lin | Construction of new retroviral producer cells from adenoviral and retroviral vectors | |
ES2184059T3 (es) | Vector retrovirico y su utilizacion en terapia genica. | |
AU3770999A (en) | Construction of retroviral producer cells from adenoviral and retroviral vectors | |
Zhao‐Emonet et al. | T Cell‐specific expression from Mo‐MLV retroviral vectors containing a CD4 mini‐promoter/enhancer | |
KR20020003215A (ko) | 기능성 및 비기능성 스플라이스 도너와 스플라이스 억셉터사이트로 구성된 레트로바이러스 벡터 | |
US6130089A (en) | Materials and methods for gene transfer | |
Blomberg et al. | Gene therapy of monogenic and cardiovascular disorders | |
Gibson et al. | Delivery of tumor suppressor genes to reverse the malignant phenotype | |
Suzuki et al. | Infection of human cells by murine ecotropic viruses: retroviral vectors carrying the hygromycin resistance-encoding gene | |
Barranger et al. | Concepts in Gene Therapy | |
Baum et al. | Retroviral Transfer and Expression of Drug Resistance Genes in Hematopoietic Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |